Risk-Based Post-Marketing Surveillance (RB-PMS2) of Antimalarial and MNCH drugs in Mali (PY2)

Background and Objectives: The advent of multi-source generic drugs has exacerbated the prevalence spread counterfeit sub-standard requiring increased vigilance collaboration from drug regulatory authorities. Post-marketing surveillance (PMS) medicines therefore plays an important role in detecting poor quality products on market. Risk-Based Post-Market Surveillance (RB-PMS) RB-PMS helps optimize resource utilization create sustainable post-market programs that are integrated implemented as a key function. Methods: survey concerned points sale identified by Technical Working Group certain geographical areas according to risk-based approaches applied selection type be targeted. It took place September December 2021 aimed assess antimalarial MNCH medicines. Results: A total 320 samples were taken analyzed protocol, which 306 compliant with rate 96% against 14 non-compliant or 4% (P≤0,05). Non-compliant both public private sectors. We found 84% unregistered among antimalarials least registered 66% 34% for came mainly India China. Conclusion: allows optimization health resources LMIC. In view its scientific nature, this sampling analysis technique must made permanent ensure guarantee access well-being populations.